Artificial Cell Technologies (ACT) is an early-stage biotechnology company developing novel vaccines utilizing a proprietary and patent-protected technology platform of ultra-thin multilayer nanofilms composed of custom-designed polypeptides. ACT uses this platform to design and produce synthetic capsules or artificial cells that mimic actual living cells, and in particular Artificial Viruses, which are artificial cells that mimic pathogenic organisms.

	ACT’s technology represents an entirely new approach to vaccines that has the potential to solve technical challenges that have prevented creation of safe and effective vaccines for certain diseases in the past. The technology is uniquely capable of more fully mimicking the immunogenic properties of a pathogenic organism and at the
ACT’s polypeptide multilayer nanofilm-based capsules or “artificial cells” that mimic pathogenic organisms: Artificial Viruses.	same time controlling the molecular and biological pathways of immune response.

• Rapid synthetic manufacture with no animal, egg, or cell culture required - greatly reduced chance of contamination and much faster to market
• Shelf stable at room temperature - no cold chain storage required

The company was established in New Haven, Connecticut in 2006.    

5 Science Park, Suite 13, New Haven CT 06511      Ph: 203.772.3430    Fx: 203.567.8073